Company Overview
Novartis AG is one of the world's largest pharmaceutical companies. Headquartered in Basel, Switzerland, the company was created in 1996 through the merger of Ciba-Geigy and Sandoz. After separating Sandoz in 2023, Novartis now operates as a more focused innovative medicines business.
The company concentrates on four core therapeutic areas: cardiovascular, renal and metabolic disease; immunology; neuroscience; and oncology. That focus has made Novartis less of a broad healthcare conglomerate and more of a research-driven pharmaceutical platform built around higher-value patented medicines.
Market Snapshot
| Metric | Latest Figure | Context |
|---|---|---|
| Market capitalization | $278.63B | CompaniesMarketCap figure for May 2026. |
| Share price | $146.03 | Quoted ADR price from CompaniesMarketCap. |
| Global rank | No. 52 | Among public companies tracked by CompaniesMarketCap. |
| One-year performance | +32.60% | Reflects the stock's prior-year move on CompaniesMarketCap. |
| TTM P/E ratio | 20.3 | CompaniesMarketCap estimate as of May 2026. |
Financial Performance
Novartis delivered a strong 2025. Net sales from continuing operations reached $54.53 billion, up 8% from 2024. Operating income rose to $17.64 billion, while net income increased to $13.97 billion. Free cash flow reached $17.60 billion.
| Financial Metric | FY 2025 | FY 2024 | Change |
|---|---|---|---|
| Net sales | $54.53B | $50.32B | +8% |
| Operating income | $17.64B | $14.54B | +21% |
| Net income | $13.97B | $11.94B | +17% |
| EPS | $7.21 | $5.92 | +22% |
| Free cash flow | $17.60B | $16.25B | +8% |
The first quarter of 2026 was more mixed. Net sales declined 1% in U.S. dollars and 5% in constant currencies to $13.11 billion. Core operating income fell 12% in U.S. dollars to $4.90 billion. Management cited U.S. generic erosion as a key drag while reaffirming full-year guidance.
Key Medicines
The investment case depends on whether growth brands can offset patent expirations and generic competition. Novartis is leaning on a group of medicines across cancer, immunology, multiple sclerosis and radioligand therapy.
| Medicine | FY 2025 Sales | Strategic Role |
|---|---|---|
| Cosentyx | $6.67B | Large immunology franchise for psoriasis and related inflammatory diseases. |
| Kisqali | $4.78B | Breast cancer medicine with strong global growth. |
| Kesimpta | $4.43B | Multiple sclerosis therapy with continued market adoption. |
| Pluvicto | $1.99B | Radioligand therapy for prostate cancer. |
| Scemblix | $1.29B | Chronic myeloid leukemia medicine with rapid growth. |
Pipeline and Capital Allocation
Research and development remains central to Novartis. The company spent $11.2 billion on R&D in 2025, up from $10.0 billion in 2024. Its official pipeline page listed 106 selected development projects, including new molecular entities, new indications and new formulations.
In 2026, Novartis completed the acquisition of Avidity Biosciences for $72 per share in cash, valuing Avidity at about $12 billion on a fully diluted basis. The deal added an antibody oligonucleotide conjugate platform and three late-stage neuromuscular disease programs.
Dividend Profile
Novartis remains relevant for income investors. Shareholders approved a dividend of CHF 3.70 per share for the 2025 business year, a 5.7% increase and the company's 29th consecutive annual dividend increase since its creation in 1996.
Risks Investors Should Watch
The biggest risk is generic erosion. Large pharmaceutical products can lose pricing power quickly when exclusivity weakens. Novartis already saw pressure from U.S. generics in early 2026.
Pricing regulation is another major risk, especially in the United States and Europe. Drug development risk also remains significant. Even a large R&D budget does not guarantee approvals, strong reimbursement or durable commercial adoption.
Bottom Line
Novartis is a profitable, cash-generative pharmaceutical leader with a market value near $279 billion. The company's challenge is clear: new growth products and pipeline assets must outrun the erosion of older blockbusters.
For investors, Novartis offers defensive healthcare exposure, dividend growth, global scale and innovation risk in one package. It is a mature pharma leader, not a speculative biotech story.
Sources: CompaniesMarketCap, Novartis FY 2025 Annual Results, Novartis Q1 2026 Results, Novartis Annual Report 2025 and Novartis Dividend Information. This article is for informational purposes only and is not financial advice.
